



(51) International Patent Classification:

C07D 403/12 (2006.01) **C07D 411/14** (2006.01)
C07D 401/14 (2006.01) **C07D 413/12** (2006.01)
C07D 405/14 (2006.01) **C07D 417/12** (2006.01)
C07D 413/14 (2006.01) **C07D 417/14** (2006.01)
C07D 401/12 (2006.01) **C07D 249/04** (2006.01)
C07D 403/14 (2006.01) **C07D 249/06** (2006.01)
C07D 405/12 (2006.01) **A61K 31/4192** (2006.01)
C07D 411/12 (2006.01)

(21) International Application Number:

PCT/JP2014/069501

(22) International Filing Date:

16 July 2014 (16.07.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/847,268	17 July 2013 (17.07.2013)	US
61/885,254	1 October 2013 (01.10.2013)	US
61/928,267	16 January 2014 (16.01.2014)	US

(71) **Applicant: OTSUKA PHARMACEUTICAL CO., LTD.**
[JP/JP]; 2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo,
1018535 (JP).

(72) **Inventors: SATO, Seiji**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **MATSUDA, Satoshi**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **MATSUMURA, Chiharu**; c/o OTSUKA PHARMACEUTICAL CO., LTD.,


3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **ITOTANI, Motohiro**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **SHINOHARA, Toshio**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **FUJITA, Shigekazu**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **SAKURAI, Yohji**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **TAI, Kuninori**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **FUKUSHIMA, Tae**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **KANEMOTO, Naohide**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **OKAMOTO, Takashi**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP).

(74) **Agent: TAKASHIMA, Hajime**; Meiji Yasuda Seimei Osaka Midouji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410044 (JP).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

[Continued on next page]

(54) Title: CYANOTRIAZOLE COMPOUNDS



(57) **Abstract:** This invention relates to a cyanotriazole compound represented by the formula (1); wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.



OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))